Neuphoria Therapeutics (NEUP) EPS (Diluted) (QoQ) (2023 - 2026)
Powered by 
Analysis
Neuphoria Therapeutics (NEUP) EPS (Diluted) (QoQ) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Neuphoria Therapeutics | 463.74 Mn | 444.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -127.09% |
| Dec 31, 2025 | 118.82% |
| Sep 30, 2025 | 34.64% |
| Jun 30, 2025 | -234.58% |
| Mar 31, 2025 | 679.52% |
| Dec 31, 2024 | -141.47% |
| Sep 30, 2024 | -171.82% |
| Jun 30, 2024 | 140.33% |
| Mar 31, 2024 | 39.00% |
| Dec 31, 2023 | 16.78% |